• The company witnessed 20% year-on-year growth in 2022-23, while the quarter-on-quarter growth was 30% in quarter 2 of the financial year 2023-24.
• This investment will help the company in building its product portfolio and enhancing its R&D prowess especially in the field of cancer.
• Leucine Rich Bio has been exporting its products to Thailand and Philippines, having exported products worth more than INR 18,00,000.

Bangalore, 23.10.2023: Known for making innovative products catering to the gut microbiome, India’s first microbiome company, Leucine Rich Bio, has raised an undisclosed amount in a pre-series A round of funding. The investment comes close to the heel of the company inaugurating a microbiome-focused gut health clinic in the heart of Bengaluru and exporting its products to the Philippines. The funding was spearheaded by prominent doctors including gastroenterologists and oncologists and biotech entrepreneurs.

The company raised its pre-seed funding worth INR 2.3 crore in 2017. Besides the Philippines, Leucine Rich Bio has been exporting its products to Thailand since 2022. So far, the company has exported products worth more than INR 1800000.

Commenting on the investment, Kumar Sankaran, CEO of Leucine Rich Bio, stated, “Receiving this investment is a testament to the groundbreaking work we are doing at Leucine Rich Bio. We truly believe in the transformative potential of the microbiome in shaping the future of healthcare, especially cancer treatment and care. With this support, we are poised to take significant strides in our mission to harness the power of the microbiome to combat various chronic diseases and cancer.”

The funds will be primarily utilised for marketing and development of new products. This investment will help the company in building its product portfolio and enhancing its R&D prowess. The company witnessed 20% year-on-year growth in 2022-23, while the quarter-on-quarter growth was 30% in quarter 2 of the financial year 2023-24. 

Leucine Rich Bio takes the practical approach to address the adage ‘All diseases begin in the gut’ by offering an innovative self-administered gut microbiome testing kit called ‘BugSpeaks’ and a dietary supplement ‘Rychbiome Indus’ that assists in making up for the necessary beneficial microorganisms in our gut. The company has a broad customer base including celebrities and regular people alike. While some health-conscious people use BugSpeaks to know about their gut health and in turn their overall well-being, others with ailments like NAFLD, IBD, IBS, type 2 diabetes, hypertension etc. have utilised the actionable BugSpeaks report (with personalised nutrition) to improve their health conditions.

Besides the popularity of BugSpeaks, the company has seen an uptick in Rychbiome Indus’ demand by 101% in the period 2022-23 vs 2021-22. 

• The company witnessed 20% year-on-year growth in 2022-23, while the quarter-on-quarter growth was 30% in quarter 2 of the financial year 2023-24.
• This investment will help the company in building its product portfolio and enhancing its R&D prowess especially in the field of cancer.
• Leucine Rich Bio has been exporting its products to Thailand and Philippines, having exported products worth more than INR 18,00,000.

Bangalore, 23.10.2023: Known for making innovative products catering to the gut microbiome, India’s first microbiome company, Leucine Rich Bio, has raised an undisclosed amount in a pre-series A round of funding. The investment comes close to the heel of the company inaugurating a microbiome-focused gut health clinic in the heart of Bengaluru and exporting its products to the Philippines. The funding was spearheaded by prominent doctors including gastroenterologists and oncologists and biotech entrepreneurs.

The company raised its pre-seed funding worth INR 2.3 crore in 2017. Besides the Philippines, Leucine Rich Bio has been exporting its products to Thailand since 2022. So far, the company has exported products worth more than INR 1800000.

Commenting on the investment, Kumar Sankaran, CEO of Leucine Rich Bio, stated, “Receiving this investment is a testament to the groundbreaking work we are doing at Leucine Rich Bio. We truly believe in the transformative potential of the microbiome in shaping the future of healthcare, especially cancer treatment and care. With this support, we are poised to take significant strides in our mission to harness the power of the microbiome to combat various chronic diseases and cancer.”

The funds will be primarily utilised for marketing and development of new products. This investment will help the company in building its product portfolio and enhancing its R&D prowess. The company witnessed 20% year-on-year growth in 2022-23, while the quarter-on-quarter growth was 30% in quarter 2 of the financial year 2023-24. 

Leucine Rich Bio takes the practical approach to address the adage ‘All diseases begin in the gut’ by offering an innovative self-administered gut microbiome testing kit called ‘BugSpeaks’ and a dietary supplement ‘Rychbiome Indus’ that assists in making up for the necessary beneficial microorganisms in our gut. The company has a broad customer base including celebrities and regular people alike. While some health-conscious people use BugSpeaks to know about their gut health and in turn their overall well-being, others with ailments like NAFLD, IBD, IBS, type 2 diabetes, hypertension etc. have utilised the actionable BugSpeaks report (with personalised nutrition) to improve their health conditions.

Besides the popularity of BugSpeaks, the company has seen an uptick in Rychbiome Indus’ demand by 101% in the period 2022-23 vs 2021-22.